Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2015 Is Released Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2015, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-inclass products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bile Duct Cancer (Cholangiocarcinoma) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bile Duct 1
Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179116/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179116/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Bile Duct Cancer (Cholangiocarcinoma) Overview 10 Therapeutics Development 11 Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview 11 Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis 12 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 13 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 18 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 22 Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 26 Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 27 2
4SC AG 27 Agios Pharmaceuticals, Inc. 28 Ariad Pharmaceuticals, Inc. 29 ArQule, Inc. 30 Array BioPharma Inc. 31 Arrien Pharmaceuticals, LLC 32 Aslan Pharmaceuticals Pte. Ltd. 33 Bayer AG 34 BIND Therapeutics, Inc. 35 Blueprint Medicines 36 Boehringer Ingelheim GmbH 37 Boston Biomedical, Inc. 38 Bristol-Myers Squibb Company 39 Celgene Corporation 40 CellAct Pharma GmbH 41 Cellceutix Corporation 42 Concordia Healthcare Corp. 43 Cornerstone Pharmaceuticals, Inc. 44 Delcath Systems, Inc. 45 Eisai Co., Ltd. 46 Eli Lilly and Company 47 Exelixis, Inc. 48 F. Hoffmann-La Roche Ltd. 49 3
Johnson & Johnson 50 Komipharm International Co., Ltd. 51 Loxo Oncology, Inc. 52 Mebiopharm Co., Ltd. 53 MedImmune, LLC 54 Merck & Co., Inc. 55 Merrimack Pharmaceuticals, Inc. 56 NanoCarrier Co., Ltd. 57 NormOxys, Inc. 58 Novartis AG 59 NuCana BioMed Limited 60 OncoTherapy Science, Inc. 61 Ono Pharmaceutical Co., Ltd. 62 Panacea Pharmaceuticals, Inc. 63 PCI Biotech AS 64 Pfizer Inc. 65 Plexxikon Inc. 66 Provecs Medical GmbH 67 Sanofi 68 Senhwa Biosciences, Inc. 69 Spectrum Pharmaceuticals, Inc. 70 Sun Pharma Advanced Research Company Ltd. 71 Threshold Pharmaceuticals, Inc. 72 VasGene Therapeutics, Inc. 73 4
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 74 Assessment by Monotherapy Products 74 Assessment by Combination Products 75 Assessment by Target 76 Assessment by Mechanism of Action 80 Assessment by Route of Administration 83 Assessment by Molecule Type 85 Drug Profiles 87 (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 87 afatinib dimaleate - Drug Profile 89 AG-120 - Drug Profile 94 ARN-5032 - Drug Profile 96 ARQ-087 - Drug Profile 97 BBI-503 - Drug Profile 98 binimetinib - Drug Profile 100 BLU-554 - Drug Profile 105 cabozantinib s-malate - Drug Profile 106 CAP-7.1 - Drug Profile 110 CC-90007 - Drug Profile 112 cisplatin - Drug Profile 115 CPI-613 - Drug Profile 117 dasatinib - Drug Profile 119 DKN-01 - Drug Profile 122 5
docetaxel - Drug Profile 124 durvalumab - Drug Profile 127 evofosfamide - Drug Profile 131 gemcitabine hydrochloride - Drug Profile 139 Im-01 - Drug Profile 140 IMB-101 - Drug Profile 141 IMB-102 - Drug Profile 142 infigratinib - Drug Profile 143 JNJ-42756493 - Drug Profile 144 KM-3174 - Drug Profile 146 KML-001 - Drug Profile 150 lenvatinib - Drug Profile 152 LOXO-101 - Drug Profile 158 MBPY-005 - Drug Profile 160 melphalan - Drug Profile 161 merestinib - Drug Profile 164 MK-2206 - Drug Profile 165 napabucasin - Drug Profile 168 nivolumab - Drug Profile 171 NUC-1031 - Drug Profile 178 OCVC-01 - Drug Profile 180 OXY-111A - Drug Profile 181 paclitaxel albumin bound - Drug Profile 183 paclitaxel albumin free - Drug Profile 187 6
PAN-622 - Drug Profile 189 pembrolizumab - Drug Profile 190 PLX-8394 - Drug Profile 199 ponatinib hydrochloride - Drug Profile 201 porfimer sodium - Drug Profile 204 refametinib - Drug Profile 206 regorafenib - Drug Profile 209 resminostat - Drug Profile 213 RRX-001 - Drug Profile 218 SAR-408701 - Drug Profile 220 seribantumab - Drug Profile 221 silmitasertib - Drug Profile 224 SPI-1620 - Drug Profile 226 sunitinib malate - Drug Profile 228 trametinib dimethyl sulfoxide - Drug Profile 232 Vaccine for Metastatic Cholangiocarcinoma - Drug Profile 235 varlitinib - Drug Profile 236 Vas-01 - Drug Profile 239 vemurafenib - Drug Profile 241 Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates 245 Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 387 Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 389 Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 390 7
Featured News & Press Releases 390 Appendix 398 Methodology 398 Coverage 398 Secondary Research 398 Primary Research 398 Expert Panel Validation 398 Contact Us 398 Disclaimer 399" width="80" height="40" />Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Bile Duct Cancer (Cholangiocarcinoma) Overview 10 Therapeutics Development 11 Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview 11 Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis 12 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 13 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 18 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 8
Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 22 Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 26 Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 27 4SC AG 27 Agios Pharmaceuticals, Inc. 28 Ariad Pharmaceuticals, Inc. 29 ArQule, Inc. 30 Array BioPharma Inc. 31 Arrien Pharmaceuticals, LLC 32 Aslan Pharmaceuticals Pte. Ltd. 33 Bayer AG 34 BIND Therapeutics, Inc. 35 Blueprint Medicines 36 Boehringer Ingelheim GmbH 37 Boston Biomedical, Inc. 38 Bristol-Myers Squibb Company 39 Celgene Corporation 40 CellAct Pharma GmbH 41 Cellceutix Corporation 42 Concordia Healthcare Corp. 43 Cornerstone Pharmaceuticals, Inc. 44 Delcath Systems, Inc. 45 Eisai Co., Ltd. 46 9
Eli Lilly and Company 47 Exelixis, Inc. 48 F. Hoffmann-La Roche Ltd. 49 Johnson & Johnson 50 Komipharm International Co., Ltd. 51 Loxo Oncology, Inc. 52 Mebiopharm Co., Ltd. 53 MedImmune, LLC 54 Merck & Co., Inc. 55 Merrimack Pharmaceuticals, Inc. 56 NanoCarrier Co., Ltd. 57 NormOxys, Inc. 58 Novartis AG 59 NuCana BioMed Limited 60 OncoTherapy Science, Inc. 61 Ono Pharmaceutical Co., Ltd. 62 Panacea Pharmaceuticals, Inc. 63 PCI Biotech AS 64 Pfizer Inc. 65 Plexxikon Inc. 66 Provecs Medical GmbH 67 Sanofi 68 Senhwa Biosciences, Inc. 69 Spectrum Pharmaceuticals, Inc. 70 10
Sun Pharma Advanced Research Company Ltd. 71 Threshold Pharmaceuticals, Inc. 72 VasGene Therapeutics, Inc. 73 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 74 Assessment by Monotherapy Products 74 Assessment by Combination Products 75 Assessment by Target 76 Assessment by Mechanism of Action 80 Assessment by Route of Administration 83 Assessment by Molecule Type 85 Drug Profiles 87 (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 87 afatinib dimaleate - Drug Profile 89 AG-120 - Drug Profile 94 ARN-5032 - Drug Profile 96 ARQ-087 - Drug Profile 97 BBI-503 - Drug Profile 98 binimetinib - Drug Profile 100 BLU-554 - Drug Profile 105 cabozantinib s-malate - Drug Profile 106 CAP-7.1 - Drug Profile 110 CC-90007 - Drug Profile 112 cisplatin - Drug Profile 115 11
CPI-613 - Drug Profile 117 dasatinib - Drug Profile 119 DKN-01 - Drug Profile 122 docetaxel - Drug Profile 124 durvalumab - Drug Profile 127 evofosfamide - Drug Profile 131 gemcitabine hydrochloride - Drug Profile 139 Im-01 - Drug Profile 140 IMB-101 - Drug Profile 141 IMB-102 - Drug Profile 142 infigratinib - Drug Profile 143 JNJ-42756493 - Drug Profile 144 KM-3174 - Drug Profile 146 KML-001 - Drug Profile 150 lenvatinib - Drug Profile 152 LOXO-101 - Drug Profile 158 MBPY-005 - Drug Profile 160 melphalan - Drug Profile 161 merestinib - Drug Profile 164 MK-2206 - Drug Profile 165 napabucasin - Drug Profile 168 nivolumab - Drug Profile 171 NUC-1031 - Drug Profile 178 OCVC-01 - Drug Profile 180 12
OXY-111A - Drug Profile 181 paclitaxel albumin bound - Drug Profile 183 paclitaxel albumin free - Drug Profile 187 PAN-622 - Drug Profile 189 pembrolizumab - Drug Profile 190 PLX-8394 - Drug Profile 199 ponatinib hydrochloride - Drug Profile 201 porfimer sodium - Drug Profile 204 refametinib - Drug Profile 206 regorafenib - Drug Profile 209 resminostat - Drug Profile 213 RRX-001 - Drug Profile 218 SAR-408701 - Drug Profile 220 seribantumab - Drug Profile 221 silmitasertib - Drug Profile 224 SPI-1620 - Drug Profile 226 sunitinib malate - Drug Profile 228 trametinib dimethyl sulfoxide - Drug Profile 232 Vaccine for Metastatic Cholangiocarcinoma - Drug Profile 235 varlitinib - Drug Profile 236 Vas-01 - Drug Profile 239 vemurafenib - Drug Profile 241 Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates 245 13
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 387 Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 389 Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 390 Featured News & Press Releases 390 Appendix 398 Methodology 398 Coverage 398 Secondary Research 398 Primary Research 398 Expert Panel Validation 398 Contact Us 398 Disclaimer 399 Read More http://www.idatainsights.com/reports-landing-page.php?id=179116/bile-duct-cancercholangiocarcinoma-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project. 14